11. ADDITIONAL EXCLUSION CRITERIA FOR non-BRAF/non-RAS MUTATION (COHORT 3): a. Patients with clinically significant hemoptysis or tumor bleeding within two weeks prior to first dose of targeted therapy. b. Patients with suspected tracheal or esophageal invasion are excluded from cohort 3 due to the high risk of tracheooesophageal fistula. Patients excluded from cohort 3 may be enrolled on taxane + atezolizumab cohort (cohort 4).